NCT07091929View on ClinicalTrials.gov

A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

November 30, 2025

Conditions
Anterior Myocardial Infarction
Interventions
DRUG

SGC001

The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.

DRUG

Placebo

The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.

Trial Locations (1)

150086

The 2nd Affiliated Hospital of Harbin Medical University, Harbin

All Listed Sponsors
lead

Beijing Sungen Biomedical Technology Co., Ltd

INDUSTRY

NCT07091929 - A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction | Biotech Hunter | Biotech Hunter